Just months after genetic-testing and health-data analytics business Sema4 Holdings Corp. combined with blank-check company CM Life Sciences Inc., it announced plans to acquire OPKO Health’s subsidiary GeneDx, Inc. in a deal valued at $623m. Blank-check companies, or SPACs as they are often called, are formed specifically to find a start-up, buy it and take it public. (Also see "Blank Check Companies’ Hunt For Innovative Medtech Start-Ups To Heat Up Further, Experts Predict" - Medtech Insight, 2 February, 2021.)
Sema4 announced on 18 January plans to buy GeneDx, which it considers a leader in rare disease diagnostic and exome...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?